🇺🇸 Nifedipine Sustained -release Tablets in United States

22 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 22

Most-reported reactions

1. Hepatic Function Abnormal — 3 reports (13.64%)
2. Off Label Use — 3 reports (13.64%)
3. Blood Pressure Increased — 2 reports (9.09%)
4. Cardiac Failure — 2 reports (9.09%)
5. Chest Pain — 2 reports (9.09%)
6. Drug-Induced Liver Injury — 2 reports (9.09%)
7. Fatigue — 2 reports (9.09%)
8. Hypokalaemia — 2 reports (9.09%)
9. Myelosuppression — 2 reports (9.09%)
10. Platelet Count Decreased — 2 reports (9.09%)

Source database →

Frequently asked questions

Is Nifedipine Sustained -release Tablets approved in United States?

Nifedipine Sustained -release Tablets does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Nifedipine Sustained -release Tablets in United States?

Hasten Biopharmaceutical Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.